26/02/2026
【論文掲載のお知らせ】
川口雄之亮先生の論文が、国際誌 Hepatology Communications に掲載されました。 Cholestasis-reducing effects of bezafibrate on survivors of biliary atresia with native livers: A prospective phase II trial https://doi.org/10.1097/hc9.0000000000000877
以下、ご本人からのメッセージです。 川口先生、おめでとうございます!
ーーーーーーーーーーーーーーーーーーーーーーー
このたび、私たちの研究成果が Hepatology Communications(Impact factor: 4.6)に掲載されました。
Title: “Cholestasis-reducing effects of bezafibrate on survivors of biliary atresia with native livers: A prospective phase II trial”
本研究は、千葉大学小児外科として初めて実施した特定臨床研究による前向き試験です。
胆道閉鎖症術後の患者さんでは、長期的に胆汁うっ滞が持続・進行するケースがあります。
本研究では、bezafibrate(ベザフィブラート)が胆汁うっ滞の改善に寄与する可能性を示す結果が得られ、成人期の胆道閉鎖症患者さんに対する新たな治療選択肢につながる知見となりました。
研究構想の段階から論文掲載まで約4年と長い道のりでしたが、今後の診療にも活かせる重要な成果になったと感じています。
今後も、臨床現場で得られる気づきや課題を研究へとつなげ、小児外科診療の向上に貢献できるよう努めてまいります。 引き続きどうぞよろしくお願いいたします。
(川口雄之亮)
[Publication Announcement]
Dr. Yunosuke Kawaguchi’s paper has been published in the international journal Hepatology Communications.
Cholestasis-reducing effects of bezafibrate on survivors of biliary atresia with native livers: A prospective phase II trial
https://doi.org/10.1097/hc9.0000000000000877
Below is a message from Dr. Kawaguchi.
Congratulations, Dr. Kawaguchi!
ーーーーーーーーーーーーーーーーーーーーーーー
We are pleased to share that our research has been published in Hepatology Communications (Impact Factor: 4.6).
Title:
“Cholestasis-reducing effects of bezafibrate on survivors of biliary atresia with native livers: A prospective phase II trial”
This study is a prospective clinical trial conducted as the first investigator-initiated specified clinical research project by the Department of Pediatric Surgery at Chiba University.
In patients who have undergone surgery for biliary atresia, long-term cholestasis may persist or progress into adulthood.
Our results suggest that bezafibrate may help improve cholestasis, providing a potential new therapeutic option for adult survivors of biliary atresia with their native liver.
From the initial research concept to publication, this project took approximately four years. We believe these findings represent an important step forward and will contribute to future clinical practice.
We will continue striving to translate clinical questions into research and advance pediatric surgical care.
Thank you for your continued support.
(Yunosuke Kawaguchi)
ivors of BA with native livers, a condition that has not been previously assessed in any study. Methods: In this single-center, single-arm, open-label, uncontrolled, prospective phase II trial, patients were enrolled from a central registry system at the Chiba University Data Center. Postoperative p...